YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
Year: 2020
Type: article
Abstract: Despite the promising clinical efficacy of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in patients with ALK-rearranged lung cancer, some tumor cells survive and eventually relapse, which may be an obstacle to achieving a cure. Limited information is currently available on the mechanisms underlying the initial survival of tumor cells against alectinib. Using patient-derived cell line models, we herein demonstrate that cancer cells survive a treatment with alectinib by activating Yes-associated protein 1 (YAP1), which mediates the expression of the anti-apoptosis factors Mcl-1 and Bcl-xL, and combinatorial inhibition against both YAP1 and ALK provides a longer tumor remission in ALK-rearranged xenografts when compared with alectinib monotherapy. These results suggest that the inhibition of YAP1 is a candidate for combinatorial therapy with ALK inhibitors to achieve complete remission in patients with ALK-rearranged lung cancer.
Source: Nature Communications
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,380
Awards: Microglial contribution on higher order of brain function and their pathology, Multidimensional analysis of microglial and synaptic contacts for understanding sensory modalities., A study on mechanisms underlying the initial survival of tumor cells against tyrosine kinase inhibitors based on patient-derived tumor models and in vivo real-time imaging, G3150132684, G4607286875, G5214277335, G5520517719, ヒトiPS細胞から肺胞上皮細胞への分化誘導手法を応用した、肺癌幹細胞の同定の研究, G8432738456, G857322337, Development of new therapeutic strategies for driver mutation-positive lung cancer
OpenAlex ID: W2997667638
